Jasper L. Van Geel

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial.

18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial.

Journal: JAMA oncology

Published: April 16, 2026

The Role of Estrogen Receptor-Targeted PET with 16α-18F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis.

The Role of Estrogen Receptor-Targeted PET with 16α-18F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 07, 2025

Comparative analysis of FES-PET/CT and FDG-PET/CT in patients with ER-positive metastatic invasive lobular breast cancer.

Comparative analysis of FES-PET/CT and FDG-PET/CT in patients with ER-positive metastatic invasive lobular breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 11, 2025

Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.

Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.

Journal: NPJ breast cancer

Published: February 11, 2025

Intrapatient 16α-[18F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.

Intrapatient 16α-[18F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: October 16, 2024

Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.

Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: February 19, 2024

Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.

Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: December 18, 2023

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

Journal: Nature cancer

Published: October 09, 2022

Molecular imaging as biomarker for treatment response and outcome in breast cancer.

Molecular imaging as biomarker for treatment response and outcome in breast cancer.

Journal: Therapeutic advances in medical oncology

Published: September 29, 2022

Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.

Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 18, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026